Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity

Chubachi, Aya; Miki, Akiko; Hayashida, Miyeko; Sakamoto, Mari; Imai, Hisanori; Kusuhara, Sentaro; Nakamura, Makoto

doi:10.3390/ph14040303

Cited by 2 publications

(2 citation statements)

References 24 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients received htPDT according to a protocol identical to that used in previous reports [ 1 , 21 ]. All patients received an infusion of verteporfin (Visudyne; Novartis, Basel, Switzerland) at 6 mg/m 2 body surface area over 10 min; laser treatment was administered 15 min after the initiation of infusion.…”

Section: Methodsmentioning

confidence: 99%

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose To compare the two-year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with and without choroidal neovascularization (CNV). Methods In this retrospective study, we included 88 eyes of 88 patients with cCSC who underwent htPDT and were followed up for more than 24 months. Patients were divided into two groups with (21 eyes) or without (67 eyes) CNV before htPDT treatment. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and the presence of subretinal fluid (SRF) were evaluated at baseline and at 1, 3, 6, 12, and 24 months after PDT. Results A significant intergroup difference was noted in terms of age (P = 0.038). Significant improvements in the BCVA and SCT were found at all time points in eyes without CNV but only at 24 months in eyes with CNV. CRT was significantly reduced in both groups at all time points. No significant intergroup differences were noted in terms of BCVA, SCT and CRT at all time points. There were significant differences in the rate of recurrent and persistent SRF between groups (22.4% (without CNV) vs. 52.4% (with CNV), P = 0.013, and 26.9% (without CNV) vs. 57.1% (with CNV), P = 0.017, respectively). The presence of CNV was significantly associated with the recurrence and persistence of SRF after initial PDT (P = 0.007 and 0.028, respectively). Logistic regression analyses showed that the baseline BCVA, and not the presence of CNV, was significantly associated with BCVA at 24 months after initial PDT (P < 0.01). Conclusions A htPDT for cCSC was less effective in eyes with CNV than in those without CNV regarding the recurrence and persistence of SRF. Additional treatment might be required in eyes with CNV during 24-month follow-up periods.

show abstract

Section: Methodsmentioning

confidence: 99%

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Various studies have reported that reduced-fluence photodynamic therapy (RFPDT) with various modifications of the standard photodynamic therapy (PDT) is effective for the complete resolution of subretinal detachment (SRD) in patients with either acute or chronic CSC 4 – 8 . However, in clinical settings, physicians encounter patients who have persistent symptoms such as micropsia despite successful treatment 9 , 10 .…”

Section: Introductionmentioning

confidence: 99%

Aniseikonia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy

Chubachi-Kamimura,

Miki,

Hayashida-Hirano

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

This study investigated aniseikonia after reduced-fluence photodynamic therapy (RFPDT) for central serous chorioretinopathy (CSC). We examined 48 eyes of 48 patients (38 men; mean age, 49.2 ± 9.9 years) with CSC resolved after RFPDT. Horizontal and vertical aniseikonia were measured using the New Aniseikonia Test at baseline, 6 months, and 12 months after RFPDT. The maximum absolute value of the horizontal and vertical measurements indicated the aniseikonia score. The aniseikonia score was 2.2 ± 2.3 at 6 months and 2.2 ± 2.0 at 12 months after RFPDT, both of which improved significantly from the baseline score of 4.1 ± 2.9 (P < 0.05 and P < 0.01, respectively). The 12-month aniseikonia score significantly correlated with the baseline aniseikonia score (P = 0.047), outer nuclear thickness at baseline (P = 0.027) and 12 months after RFPDT (P = 0.014), baseline SRD area (P = 0.005), and ellipsoid zone disruption at 12 months after RFPDT (P = 0.021). In multivariate analysis, baseline serous retinal detachment (SRD) area (P = 0.034) was significantly associated with aniseikonia score at 12 months after RFPDT. Eyes with a larger SRD area might have higher aniseikonia scores even after SRD resolution following RFPDT.

show abstract

Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity

Cited by 2 publications

References 24 publications

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

Aniseikonia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy

Contact Info

Product

Resources

About